---
title: "Vertex Pharmaceuticals Q4 Non-GAAP Net Income Falls, Revenue Rises; 2025 Outlook Set"
date: "2025-02-11 05:10:40"
summary: "Vertex Pharmaceuticals reported Q4 non-GAAP net income late Monday of $3.98 per diluted share, down from $4.20 a year earlier. Analysts polled by FactSet expected $4.02. Product revenue for the quarter ended Dec. 31 was $2.91 billion, up from $2.52 billion a year earlier. Analysts surveyed by FactSet forecast $2.78..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Vertex Pharmaceuticals reported Q4 non-GAAP net income late Monday of $3.98 per diluted share, down from $4.20 a year earlier.

Analysts polled by FactSet expected $4.02.

Product revenue for the quarter ended Dec. 31 was $2.91 billion, up from $2.52 billion a year earlier.

Analysts surveyed by FactSet forecast $2.78 billion.

The biotech firm expects fiscal 2025 revenue of $11.75 billion to $12 billion. Analysts polled by FactSet are looking for $11.84 billion.

Shares of Vertex Pharmaceuticals were up 1.2% in after-hours trading.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:A3313868:0/)
